Efficacy and Safety of Endoscopic Sleeve Gastroplasty Versus Laparoscopic Sleeve Gastrectomy in Obese Subjects With NASH

  • STATUS
    Recruiting
  • End date
    Jun 1, 2023
  • participants needed
    30
  • sponsor
    Instituto de Investigación Marqués de Valdecilla
Updated on 26 January 2021

Summary

The primary objectives of this study are to evaluate the effect of ESG with OverStitch system (Apollo Endosurgery, Austin, TX, USA) compared to LSG on 1) histological improvement in NASH; 2) all-cause mortality and liver-related outcomes In obese subjects with non-alcoholic steatohepatitis (NASH).

Condition or disease: Non-alcoholic steatohepatitis (NASH) with or without fibrosis Intervention/treatment: ESG with OverStitch system vs LSG

Details
Condition Non Alcoholic Steatohepatitis
Treatment Endoscopic Sleeve Gastroplasty (ESG) with OverStitch® system + Lifestyle modifications, Laparoscopic Sleeve Gastrectomy (LSG) + Lifestyle modifications
Clinical Study IdentifierNCT04060368
SponsorInstituto de Investigación Marqués de Valdecilla
Last Modified on26 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Subjects aged between 18 and 60 years (inclusive) at first screening visit
Must provide signed written informed consent and agree to comply with the study protocol
BMI between 35 and 45 kg/m2 with or without metabolic risk factors (type 2 diabetes, arterial hypertension, dyslipidaemia), and BMI between 30 and 34,9 kg/m2 with type 2 diabetes
Histological confirmation of steatohepatitis in a diagnostic liver biopsy (biopsy obtained in the 6 months prior to randomization or during the selection period) with at least a score of 1 in each component of the NAS score (steatosis with a score of 0 to 3, degeneration by ballooning with a score of 0 to 2 and lobular inflammation with a score of 0 to 3) and
NAS score 4
fibrosis < 4 according to the staging system of CRN fibrosis on NASH
For patients with fibrosis 1, must be associated at least one of the following conditions: metabolic syndrome (NCEP ATP III definition), type 2 diabetes, HOMA-IR >6
Absence of other well documented causes of chronic liver disease (alcoholic liver disease, viral hepatitis, cholestasis, autoimmune hepatitis, Wilson's disease, hemochromatosis, alpha 1 antitrypsin deficiency)
Patients agree to have 1 liver biopsy after 96 weeks after intervention

Exclusion Criteria

Known heart failure (Grade I to IV of the classification of the New York Heart Association)
History of efficient bariatric surgery within 10 years prior to Screening
Patients with a history of clinically significant acute cardiac event in the 6 months prior to selection, such as: acute cardiovascular event, cerebrovascular accident, transient ischemic attack, or coronary heart disease (angina pectoris, myocardial infarction, revascularization procedures)
Weight loss of more than 5% in the 6 months prior to randomization
Recent or current background of significant consumption of alcoholic beverages (<5 years). In the case of men, significant consumption is usually defined as more than 30 g of pure alcohol per day. In the case of women, it is usually defined as more than 20 g of pure alcohol per day
Liver cirrhosis
Non-cirrhotic portal hypertension
Esophagogastric varices
Hepatocellular carcinoma
Portal thrombosis
Pregnancy
Refusal to give informed consent
Any medical condition that could reduce life expectancy to less than 2 years, including known cancers
Signs of any other unstable or clinically significant immunological, endocrine, hematological, gastrointestinal, neurological, neoplastic or psychiatric disease without treatment
Instability or mental incompetence, so that the validity of the informed consent or the ability to comply with the study are uncertain
Antibodies positive for the human immunodeficiency virus
Descompensated liver disease with the following hematologic and biochemical criteria
Aspartate aminotransferase (AST) and / or ALT> 10 x upper limit of normal (ULN)
Total bilirubin> 25 mol / l (1.5 mg / dl)
Standardized international index> 1.4
Platelet count <100 000 / mm3
Serum creatinine levels> 135 mol / l (> 1.53 mg / dl) in men and> 110 mol / l (> 1.24 mg / dl) in women
Significant renal disease, including nephritic syndrome, chronic kidney disease (patients with markers of hepatic injury or estimated glomerular filtration rate [eGFR] of less than 60 ml / min / 1.73 m2). If an abnormal value is obtained at the first screening visit, the eGFR measurement may be repeated before randomization within the following time frame: minimum 4 weeks after the initial test and maximum 2 weeks before the expected randomization. An abnormal repeated eGFR (less than 60 ml / min / 1.73 m2) leads to exclusion from the study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note